Skip to content

Nodal T Follicular Helper Cell Lymphoma Follicular Type C2700204

Published: July 22, 2026Updated: August 20, 2026

A rare type of non-Hodgkin lymphoma affecting immune cells in the lymph nodes. Typically occurs in adults and is treated with chemotherapy, immunotherapy, or targeted therapies depending on the stage.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Bone marrow involvement

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Painless lymphadenopathy

(hematologic)

Fever

(hematologic)

Night sweats

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination chemotherapy regimen

Multi-agent chemotherapy protocols typically including anthracyclines and alkylating agents designed to achieve complete remission in aggressive lymphoma.

medication
2

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Immunotherapy with monoclonal antibodies

Targeted therapy using anti-CD antibodies that enhance immune-mediated destruction of malignant T-follicular helper cells.

medication

Additional treatment options

Radiation therapy

Localized radiation targeting involved lymph node regions, particularly for early-stage disease or residual disease after chemotherapy.

procedure

Autologous stem cell transplantation

High-dose chemotherapy followed by stem cell rescue for eligible patients with relapsed or refractory disease achieving remission.

surgical

Surveillance imaging and labs

Regular PET-CT scans and tumor markers to detect relapse early, typically performed every 3-6 months for the first two years.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Nodal T Follicular Helper Cell Lymphoma Follicular Type C2700204?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Nodal T Follicular Helper Cell Lymphoma Follicular Type C2700204. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy